# A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Study · id `cardio:ct-nct02681094` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02681094](<https://clinicaltrials.gov/study/NCT02681094>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02681094

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 905 participants.

## Technical summary

Registry record NCT02681094. Randomized; triple masking; primary purpose treatment. Start 2016-02-26 (actual); primary completion 2017-07-15 (actual). Results posted on 2018-10-10.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 905 participants (enrolled count; ClinicalTrials.gov record NCT02681094, source copy `cardio:ctgov-nct02681094-2018-10-10`, retrieved 2026-10-26)
- Started: 2016-02-26 (actual) (ClinicalTrials.gov record NCT02681094, source copy `cardio:ctgov-nct02681094-2018-10-10`, retrieved 2026-10-26)
- Primary completion: 2017-07-15 (actual) (ClinicalTrials.gov record NCT02681094, source copy `cardio:ctgov-nct02681094-2018-10-10`, retrieved 2026-10-26)
- Completion: 2017-07-15 (actual) (ClinicalTrials.gov record NCT02681094, source copy `cardio:ctgov-nct02681094-2018-10-10`, retrieved 2026-10-26)
- Results first posted: 2018-10-10 (ClinicalTrials.gov record NCT02681094, source copy `cardio:ctgov-nct02681094-2018-10-10`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Germany; Mexico; Russia (ClinicalTrials.gov record NCT02681094, source copy `cardio:ctgov-nct02681094-2018-10-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02681094-2018-10-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Condition: Inadequate Glycaemic Control
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo for Dapagliflozin
- Intervention (Drug): Saxagliptin
- Intervention (Drug): Placebo for Saxagliptin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: ad4c066c4f21f3d8699a3b8e809bf8ca041151e70d1310368fdc4817cd3774eb
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
